SCHEMBL6444732

SCHEMBL6444732

O=[C]Cc1ccccc1N(Cc1ccccc1)c1c(Cl)cccc1Cl

nearest known ligand 0.40

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
NR3C1 P04150 1/20 0.38
TRPM8 Q7Z2W7 1/20 0.35
CYP2D6 P10635 1/20 0.34
CYP2C9 P11712 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
MEN1 O00255 5/20 0.34
KMT2A Q03164 5/20 0.34
LMNA P02545 3/20 0.34
PMP22 Q01453 1/20 0.34
TAS2R14 Q9NYV8 1/20 0.34
TDP1 Q9NUW8 1/20 0.33
ALDH1A1 P00352 1/20 0.33
EGFR P00533 1/20 0.32
ERBB2 P04626 1/20 0.32
SIGMAR1 Q99720 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10802924 0.81 CXCL8 (0.46) TAS2R14TDP1SIGMAR1
SCHEMBL27334726 0.77 TRPM8 (0.55) NR3C1TRPM8MEN1KMT2ATAS2R14
SCHEMBL11415072 0.76 MMP1 (0.40) NR3C1CYP2C9MAPK1MEN1KMT2A
SCHEMBL10439811 0.74 CYP2D6 (0.36) NR3C1TRPM8CYP2D6CYP2C9TSHR
SCHEMBL11419100 0.74 P2RX7 (0.43) NR3C1TRPM8CYP2C9MAPK1KMT2A
SCHEMBL11412916 0.73 NR3C1 (0.37) NR3C1MEN1KMT2ALMNAALDH1A1
SCHEMBL11413423 0.73 PTGS2 (0.43) NR3C1MEN1KMT2ALMNA
SCHEMBL11571010 0.69 PTGS2 (0.42) CYP2C9TSHRMAPK1MEN1KMT2A
SCHEMBL2095814 0.69 TRPM8 (0.38) TRPM8TSHRLMNAALDH1A1SIGMAR1
SCHEMBL96464 0.69 TAAR1 (0.52) CYP2D6CYP2C9TSHRLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0255082-B1 Renin-inhibiting di- and tripeptides, methods for their production, drugs containing them, and their use HOECHST AG (DE) 1993-12-01 EP claimed
EP-0184550-B1 5-AMINO-4-HYDROXY VALERYL AMIDE DERIVATIVES CIBA-GEIGY AG (CH) 1992-03-18 EP claimed
EP-0394829-A1 Renin-inhibiting dipeptides, process to synthetize them, compositions containing them and their use HOECHST AKTIENGESELLSCHAFT (DE) 1990-10-31 EP claimed
US-4863903-A RENIN ENZYME INHIBITORS, HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1989-09-05 US claimed
US-4855286-A HYPOTENSIVE AGENTS HOECHST AKTIENGESELLSCHAFT (DE) 1989-08-08 US claimed
US-4727060-A HYPOTENSIVE AGENTS CIBA-GEIGY CORPORATION (US) 1988-02-23 US claimed
EP-0255082-A2 Renin-inhibiting di- and tripeptides, methods for their production, drugs containing them, and their use HOECHST AKTIENGESELLSCHAFT (DE) 1988-02-03 EP claimed
EP-0184550-A2 5-Amino-4-hydroxy valeryl amide derivatives CIBA-GEIGY AG (CH) 1986-06-11 EP claimed
EP-0143746-A2 5-Amino 4-hydroxy-valeryl-substituted derivatives CIBA-GEIGY AG (CH) 1985-06-05 EP claimed
US-20050130941-A1 Methods of treating alzheimer's disease PHARMACIA & UPJOHN COMPANY LLC 2005-06-16 US disclosed
US-5753652-A Antiretroviral hydrazine derivatives NOVARTIS CORPORATION (US) 1998-05-19 US disclosed
EP-0521827-B1 Pharmacological active hydrazin derivatives and process for their preparation CIBA GEIGY AG (CH) 1996-09-25 EP disclosed
EP-0255082-B1 Renin-inhibiting di- and tripeptides, methods for their production, drugs containing them, and their use HOECHST AG (DE) 1993-12-01 EP disclosed
EP-0521827-A1 Pharmacological active hydrazin derivatives and process for their preparation CIBA-GEIGY AG (CH) 1993-01-07 EP disclosed
EP-0255082-A2 Renin-inhibiting di- and tripeptides, methods for their production, drugs containing them, and their use HOECHST AKTIENGESELLSCHAFT (DE) 1988-02-03 EP disclosed
US-4719288-A HYPOTENSIVE CIBA-GEIGY CORPORATION (US) 1988-01-12 US disclosed
EP-0230242-A2 Substituted derivatives of 4-amino-3-hydroxy-butyric acid, process for their production, medicines containing them, and their use HOECHST AKTIENGESELLSCHAFT (DE) 1987-07-29 EP disclosed
US-4613676-A PEPTIDES CIBA-GEIGY CORPORATION (US) 1986-09-23 US disclosed
EP-0184550-A2 5-Amino-4-hydroxy valeryl amide derivatives CIBA-GEIGY AG (CH) 1986-06-11 EP disclosed
EP-0143746-A2 5-Amino 4-hydroxy-valeryl-substituted derivatives CIBA-GEIGY AG (CH) 1985-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050130941-A1 Methods of treating alzheimer's disease BACE1, PSEN1, BACE2 NR3C1 1548/4885TRPM8 3777/4885CYP2D6 3661/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.